Reshma Kewalramani
Chief Executive Officer and President
2020 – Present
6 years (current)
Key Decisions & Impact
Taking complete, aggressive control as the experienced, brilliant medical executive, Reshma Kewalramani orchestrated an urgent strategic pivot to diversify Vertex's but concentrated cystic fibrosis portfolio. She drove the brilliant development and approval of Casgevy, heavily prioritizing lucrative CRISPR gene-editing partnerships over isolated internal research. Most when patent cliffs threatened future revenue, she masterminded a complex, strategic multi-year pipeline expansion, focusing on executing aggressive trials for the non-opioid painkiller suzetrigine and acquiring Alpine Immune Sciences for kidney disease.
Legacy
Kewalramani's defining mandate is literally proving that the specialized cystic fibrosis monopoly can financially evolve into a diversified genetic medicine powerhouse. By executing an aggressive focus on groundbreaking rare disease approvals and leveraging the Trikafta cash flow, she defended corporate relevance and secured the next decade of astronomical revenue growth. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability.